use of 2-methylene-19-nor- (20s) -1alpha, 25-dihydroxycivilamine d3 for the treatment of secondary hyperparathyroidism

摘要

Summary use of 2-methylene-19-nor- (20s) -1alpha, 25-dihydroxycivamine d3 for the treatment of secondary hyperparathyroidism (pt) describes the use of 2-methy1ene-i9-nor- (20s) -la, 25-dihydroxwitamin d3 to treat and / or prevent secondary hyperparathyroidism and / or its accompanying symptoms in a subject with or at risk of developing secondary hyperparathyroidism without inducing hypercalcemia in the subject.